Evotec AG's near-term partnering options narrowed on news that its smoking cessation drug EVT 302 failed to demonstrate efficacy in a Phase II proof-of-concept trial involving 414 smokers. (BioWorld International)

BioXell SpA suffered a collapse in its share price following news that its vitamin D3 analogue elocalcitol failed to meet the primary endpoint of a Phase IIb trial in overactive bladder (OAB). (BioWorld International)